NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

I think I know what you mean in reference to the FDA . The FDA approved the trial to resume in full force after its halt.

The FDA and NIH work very closely together. Highly reputable licensed professionals have vetted the immunotherapy research of Dr. Liau, I would recommend that you research and study for yourself the recent 590 million dollar grant that was awarded to UCLA. The U.S. government NIH grant is funded by tax dollars and is public record for anyone who wants to see it. Within its many many pages, you will find many professionals who have reviewed the immunotherapy work of Dr. Liau.

The NIH peer-reviewed grant is the source of funding being used today to dose patients with DCVax-L and Keytruda.

https://clinicaltrials.gov/ct2/show/NCT04201873

Department of Neurosurgery Chair Linda M. Liau, MD, PhD, MBA, was a leading recipient of NIH grants – No. 3 in the nation within the discipline.

“It's the stamp of approval from the NIH, because these types of grants are so rigorously peer-reviewed,” Dr. Liau says. “People get funded based on the strength of the science and that, itself, is very powerful in terms of showing that our research is scientifically valid and meaningful and hopefully will lead to future treatments.”

The NIH is a much better source than I am or that anyone on social media is or anyone on a stock message board. Researching the peer review of a large recent government grant is an example of research that is more reliable than a stock message board is. Anyone can go look at the grant for themselves and review the professional vetting of its recipients.

NIH and the FDA tell us that they are well-coordinated they assert that work closely together on the development of new technologies.

https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/